HMHeidi Mertes

Heidi Mertes

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Heidi Mertes has a total of 157 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Sharing new genetic risk information with recipients of donor gametes

    by Dorian Accoe, Guido Pennings, Sandra Janssens, Frauke Vanden Meerschaut, Kelly Tilleman, Heidi Mertes

  • Open Access

    Is Digital Healthcare Better Than None? The Digital Health Technology Dilemma in Low-Income Countries

    by Brandon Ferlito, Heidi Mertes

    Digital health technologies (DHTs) are often promoted as solutions to healthcare access challenges in low-income countries (LICs), where a lack of infrastructure, healthcare professionals, and regulatory capacity makes them especially appealing. In such contexts, DHTs can provide services that would otherwise remain out of reach. Yet their implementation raises significant ethical and regulatory concerns. These concerns are heightened in LICs, where technologies designed in high-income countries may perform less reliably, accountability is weak, and corporate interests often dominate development and governance. This paper compares DHTs with Early Access Programmes (EAPs) for investigational therapies, both of which involve offering imperfect interventions under conditions of uncertainty. While EAPs are tightly regulated, DHTs are often introduced with limited oversight and marketed as final solutions. Unlike pharmaceuticals, which carry immediate risks such as severe side effects, the risks associated with DHTs are typically indirect or delayed, manifesting through misdiagnoses, breaches of privacy and confidentiality, digital inequalities, and the erosion of trust in healthcare systems. Using examples from Uganda and Malawi, the analysis highlights how permissive adoption risks promoting a ‘better than nothing’ standard of care, while rigid regulation may deny immediate benefits. We argue for a tiered approach: conditional, context-sensitive oversight that expands access without normalising lower standards of care, embedding privacy, confidentiality, equity, and accountability as central design criteria.

  • Risk management and the further use of gametes from a donor with a known pathogenic variant

    by Dorian Accoe, Guido Pennings, Sandra Janssens, Heidi Mertes

    Some donor-conceived persons are born with an autosomal recessive genetic condition. In response, some fertility clinics categorically restrict the further use of the gametes from the donor who transmitted the pathogenic variant, although the chance of recurrence is usually very low. The level of specific risk that a recipient or physician is willing to accept depends on various factors, including severity, lived experiences and personal preferences. However, on a policy level, we argue for consistency and guidance on the principled question of whether the (further) use of gametes from donors who are carriers of a known pathogenic variant with autosomal recessive inheritance is acceptable. Provided that the identified risk is comparable to the general risk of genetic conditions, the continued use of the donor gametes can remain an acceptable option.

  • Open Access

    To err is human, also in medically assisted reproduction: a cross-sectional study on error management practices

    by Alessandra Alteri, Kelly Tilleman, Nathalie Vermeulen, Giuliana Baccino, Kenny A Rodriguez-Wallberg, Arianna D’aNgelo, Theofano Bounartzi, Zdravka Veleva, Heidi Mertes

    STUDY QUESTION: How do medically assisted reproduction (MAR) centres manage errors, and what are the practices for reporting adverse incidents and non-conformities to National Competent Authorities (NCA) and disclosing them to patients? SUMMARY ANSWER: The study reveals a diverse landscape of error management practices in MAR centres, with varying approaches to reporting and disclosure, emphasizing a mix of transparency and systematic management of non-conformities. WHAT IS KNOWN ALREADY: Previous studies have highlighted the critical nature of error management in MAR settings which are inherently susceptible to errors due to their complexity. Despite this recognition, comprehensive data on error management practices across different MAR centres have been limited. STUDY DESIGN, SIZE, DURATION: A cross-sectional study was set up to gather data on the current practice with regards to error management at MAR centres. Data were collected between 25 April and 25 May 2022. PARTICIPANTS/MATERIALS, SETTING, METHODS: An online survey was designed, using the online SurveyMonkey tool, to consist of 17 questions concerning three domains: error management in the MAR centre, reporting to NCA and disclosure of non-conformities to patients. The survey was distributed to professionals working in MAR centres through the ESHRE membership mailing list. MAIN RESULTS AND THE ROLE OF CHANCE: A total of 464 replies were received and following exclusion of invalid results, the final dataset included the replies of 387 respondents. A majority, ∼71.6% of respondents, confirmed that both laboratory and clinical non-conformities are systematically recorded, predominantly using digital platforms. Mainly, all types of errors are recorded based on their severity, including near-misses. In terms of discussing incidents, about 85.8% of the centres reported that they regularly hold meetings to review them. However, practices varied considerably when it came to reporting non-conformities to the NCA and disclosing them to patients. Only 15.1% of respondents reported all types of incidents (major, moderate, and significant) to the NCA, while a significant portion, 65.6%, indicated that they report only major incidents. Concerning disclosure practices to patients, a majority (52%) stated that their centres always communicate incidents to patients, indicating a trend towards transparency in patient care. However, 11.7% of respondents mentioned that they do not disclose to patients, highlighting a gap in proactive patient communication in some centres. LIMITATIONS, REASONS FOR CAUTION: The study’s sample may not be representative of all MAR centres, with a potential bias towards practices in countries with higher respondent rates (Spain, UK, Italy); also the possibility of having received multiple responses from the same centre could not be ruled out. Additionally, despite survey anonymity, there may be a tendency for respondents to provide socially desirable answers. WIDER IMPLICATIONS OF THE FINDINGS: These findings contribute to a broader understanding of error management in MAR centres worldwide, highlighting the need for standardized reporting systems and more transparent communication with patients. This study also underscores the importance of fostering a culture of safety and continuous learning from non-conformities in the MAR sector. STUDY FUNDING/COMPETING INTEREST(S): K.T. disclosed support for attending meetings and/or travel from Ferring, Cooper Surgical, Fujifilm, and Vitrolife group. K.R.-W. disclosed support from Radiumhemmets Forskningsfonder and The Swedish Cancer Society; grants from Swedish Research Council, Swedish Cancer Society, Swedish Childhood Cancer Fund, Radiumhemmets Forskningsfonder, Stockholm County Council FoU, Karolinska Institutet and IngaBritt och Arne Lundbergs Forskningsstiftelse; royalties; consulting fees from the Swedish Ministry of Health and Welfare; honoraria from Roche (for chairmanship and lectures), Pfizer (for chairmanship and lectures), Organon (lectures), and IBSA (Advisory Board for educational event); support for meetings and/or travel from Organon and Regionstockholm; participation at advisory boards for Merck and Ferring; receipt of equipment from Merck and Ferring. Z.V. disclosed research grants from ESHRE and Juhani Aaltonen Foundation; and support for meetings and/or travel from ESHRE. The other authors had no competing interests to disclose. TRIAL REGISTRATION NUMBER: N/A.


  • On misempowerment & mobile health

    by Jesse Gray, Heidi Mertes

    Mobile health tools often claim to empower their users by giving them the knowledge they need to take control of their health. However, this notion of empowerment, what we refer to as the knowledge-control paradigm, only superficially engages with the concept and leaves out the different ways in which people come to be empowered. We first identify two distinct elements of empowerment: psychological empowerment, which pertains to beliefs about one’s power and control over their health, and relational empowerment, which is connected with one’s actual power to control their health, as well as the ability to hold those in positions of power (the empowered) accountable. The knowledge-control paradigm is incapable of creating empowered individuals in the relational sense, and it is only when knowledge is coupled with both the means and the motivations to control health and/or hold the empowered to account, that one can be considered empowered. Mobile health tools that overemphasize knowledge as the empowering mechanism often misempower their users, that is, they create a belief in users about their power to control their health that does not align with their actual capacity to do so. This mismatch between beliefs and reality can have far reaching consequences as with knowledge, ability, control, and power comes responsibility. We worry not only that the misempowered will be viewed as more responsible for their health than the circumstances permit, but also, that these individuals will lose the ability to hold those in positions of power accountable..


  • Genetic and reproductive strategies to prevent mitochondrial diseases

    by Noemi Castelluccio, Katharina Spath, Danyang Li, Irenaeus F M De Coo, Lyndsey Butterworth, Dagan Wells, Heidi Mertes, Joanna Poulton, Björn Heindryckx

    Mitochondrial DNA (mtDNA) diseases pose unique challenges for genetic counselling and require tailored approaches to address recurrence risks and reproductive options. The intricate dynamics of mtDNA segregation and heteroplasmy shift significantly impact the chances of having affected children. In addition to natural pregnancy, oocyte donation, and adoption, IVF-based approaches can reduce the risk of disease transmission. Prenatal diagnosis (PND) and preimplantation genetic testing (PGT) remain the standard methods for women carrying pathogenic mtDNA mutations; nevertheless, they are not suitable for every patient. Germline nuclear transfer (NT) has emerged as a novel therapeutic strategy, while mitochondrial gene editing has increasingly become a promising research area in the field. However, challenges and safety concerns associated with all these techniques remain, highlighting the need for long-term follow-up studies, an improved understanding of disease mechanisms, and personalized approaches to diagnosis and treatment. Given the inherent risks of adverse maternal and child outcomes, careful consideration of the balance between potential benefits and drawbacks is also warranted. This review will provide critical insights, identify knowledge gaps, and underscore the importance of advancing mitochondrial disease research in reproductive health.


  • Open Access

    Ethical considerations on surrogacy

    by Writing Group on behalf of the ESHRE Ethics Committee, Francoise Shenfield, Basil Tarlatzis, Guiliana Baccino, Theofano Bounartzi, Lucy Frith, Guido Pennings, Veerle Provoost, Nathalie Vermeulen, Heidi Mertes

    Surrogacy is the assisted reproductive technology (ART) practice in which a person becomes pregnant, carries, and delivers a child on behalf of another couple/person, who are the intended parent(s). Surrogacy is an especially complex practice as the interests of the intended parents, the gestational carrier, and the future child may differ. This paper considers ethical questions related to different forms of surrogacy. It concludes that non-commercial surrogacy is an acceptable method of assisted reproduction for specific indications. When using surrogacy to form a family, it is essential that there are measures to protect all parties, to guarantee well-considered decision-making, and to minimize risks. The current paper formulates recommendations to promote these measures. This paper is an update to the ESHRE Task Force Ethics and Law Paper 10: Surrogacy and replaces this paper.


  • Top Cited Papers
    Open Access

    Ethical considerations on the moral status of the embryo and embryo-like structures

    by Writing Group of the ESHRE Ethics Committee, Guido Pennings, Wybo Dondorp, Mina Popovic, Susana Chuva de Sousa Lopes, Heidi Mertes

    The current article provides an ethical reflection on the moral status of the human embryo, which is a crucial factor in determining permissible actions involving embryos and the extent of their protection. It advocates for the extension of the research period for embryos to 28-days post fertilization. It also states that integrated embryo-like structures (ELSs) should not currently be given the same moral status as natural embryos. However, if they pass the relevant tests, they should be subject to the same rules as natural embryos.


  • Top Cited Papers
    Open Access

    Responsibility Gap(s) Due to the Introduction of AI in Healthcare: An Ubuntu-Inspired Approach

    by Brandon Ferlito, Seppe Segers, Michiel De Proost, Heidi Mertes

    Due to its enormous potential, artificial intelligence (AI) can transform healthcare on a seemingly infinite scale. However, as we continue to explore the immense potential of AI, it is vital to consider the ethical concerns associated with its development and deployment. One specific concern that has been flagged in the literature is the responsibility gap (RG) due to the introduction of AI in healthcare. When the use of an AI algorithm or system results in a negative outcome for a patient(s), to whom can or should responsibility for that outcome be assigned? Although the concept of the RG was introduced in Anglo-American and European philosophy, this paper aims to broaden the debate by providing an Ubuntu-inspired perspective on the RG. Ubuntu, deeply rooted in African philosophy, calls for collective responsibility, and offers a uniquely forward-looking approach to address the alleged RG caused by AI in healthcare. An Ubuntu-inspired perspective can serve as a valuable guide and tool when addressing the alleged RG. Incorporating Ubuntu into the AI ethics discourse can contribute to a more ethical and responsible integration of AI in healthcare.